Mariana González-Treviño

Mariana González-Treviño

Auto-generated profile, based on publicly available information

Mariana González-Treviño

Division of Rheumatology Mayo Clinic Rochester Minnesota

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

19 February 2022 in Cytotherapy
Verified
Journal Article
Closed access
JJJosé Carlos Jaime-Pérez
José Carlos Jaime-Pérez
JMJesús D. Meléndez-Flores
Jesús D. Meléndez-Flores
EREugenia M. Ramos-Dávila
Eugenia M. Ramos-Dávila
MGMariana González-Treviño
Mariana González-Treviño
DGDavid Gómez-Almaguer
David Gómez-Almaguer

29 September 2021 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
JJJosé Carlos Jaime-Pérez
José Carlos Jaime-Pérez
MGMariana González-Treviño
Mariana González-Treviño
JMJesús D. Meléndez-Flores
Jesús D. Meléndez-Flores
EREugenia M. Ramos-Dávila
Eugenia M. Ramos-Dávila
OCOlga G. Cantú-Rodriguez
Olga G. Cantú-Rodriguez
DGDavid Gómez-Almaguer
David Gómez-Almaguer

27 January 2021 in Expert Review of Hematology
Verified
Journal Article
Closed access
JJJosé Carlos Jaime-Pérez
José Carlos Jaime-Pérez
MGMariana González-Treviño
Mariana González-Treviño
DGDavid Gómez-Almaguer
David Gómez-Almaguer
Introduction: Pregnancy-associated aplastic anemia (pAA) occurs when aplastic anemia (AA) is diagnosed for the first time during pregnancy and it is a rare but serious condition leading to severe maternal and fetal complications. It is unknown whether pregnancy triggers bone marrow failure or if this state is unrelated to the pathogenesis of pAA. Areas covered: In this review, three new cases of pAA are presented and its controversial etiologic relationship with pregnancy, its atypical presentation, and management are also discussed. Furthermore, a literature review of pAA cases between 1975 and 2020 was performed in PubMed, accessed via the National Library of Medicine PubMed interface. Keywords included “aplastic anemia” AND “pregnancy”. We found 54 cases reported in the literature with a clear diagnosis of pAA. Expert opinion: The diagnosis of pAA is challenging since pregnancy is associated with physiologic hematological changes in the complete blood count which can mask the disease. Meticulous monitoring and adequate support therapy given by a trained multidisciplinary team have the potential to improve outcomes for women and their neonates. All women should receive frequent assessments to optimize their care during pregnancy and after delivery, definitive treatment should be offered.

27 May 2021 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
PCPerla R. Colunga-Pedraza
Perla R. Colunga-Pedraza
JCJulia E. Colunga-Pedraza
Julia E. Colunga-Pedraza
JMJesús D. Meléndez-Flores
Jesús D. Meléndez-Flores
MGMariana González-Treviño
Mariana González-Treviño
EREugenia M. Ramos-Dávila
Eugenia M. Ramos-Dávila
JJJosé C. Jaime-Pérez
José C. Jaime-Pérez

18 November 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
MGMariana González-Treviño
Mariana González-Treviño
GFGabriel Figueroa-Parra
Gabriel Figueroa-Parra
JYJeffrey X Yang
Jeffrey X Yang
LPLarry Prokop
Larry Prokop
SGSherif M Gamal
Sherif M Gamal
ADAlí Duarte-García
Alí Duarte-García
To assess the association of antiphospholipid antibodies (aPL) and diffuse alveolar hemorrhage (DAH) in patients with systemic lupus erythematosus (SLE) by performing a systematic review and meta-analysis. Multiple databases were systematically searched from inception to February 2024. Studies were eligible if they included patients with SLE (population), reported aPL status (exposure), and DAH (outcome). We pooled the estimates as odds ratio (OR) using fixed-effect models. We examined the association between aPL and DAH, as well as associations based on aPL subtypes or concomitant antiphospholipid syndrome (APS). Out of 454 screened studies, nine were included in meta-analysis, encompassing 7,746 patients with SLE, of whom 2016 (26.0%) were aPL positive and 163 (2.1%) had DAH. Patients with SLE and positive aPL (any) were more likely to develop DAH than aPL-negative patients (OR = 1.76, 95% CI 1.24–2.49; I2= 0%). Patients with SLE and positive lupus anticoagulant (LA; OR = 1.76, 95% CI 1.06–2.93, I2= 35%) or positive anticardiolipin IgG (OR = 1.62, 95% CI 1.13–2.34, I2=0%) had a higher likelihood of developing DAH compared with patients that were negative for these aPL. An APS diagnosis was associated with a 2.5-fold increased likelihood of DAH compared with subjects without APS (OR = 2.46, 95% CI 1.23–4.92, I2=0%). Positivity of anti-β2 glycoprotein I IgG was not significantly associated with DAH among patients with SLE (OR = 0.78, 95% CI 0.45–1.36, I2=0%). In patients with SLE, aPL positivity increases the risk of DAH compared with aPL-negative patients, particularly in those positive for LA and anticardiolipin IgG.